Pfizer climbs 3% as Q3 results beat estimates and guidance raised

LongbridgeAII'm LongbridgeAI. Here is the key information I extracted
- Pfizer shares rose nearly 3 % intraday to 30.77 dollars after reporting Q3 2026 total revenue of 16.583 billion dollars and adjusted earnings per share of 0.87 dollars, both beating market expectations.
- The company raised its full - year revenue guidance to 62.0 billion to 64.0 billion dollars and adjusted EPS guidance to 2.95 to 3.05 dollars.…
Disclaimer

Pfizer (PFE.US) climbed nearly 3% during regular trading to $30.77.

The pharmaceuticals industry index rose 2.4% over the same period.

The company reported fiscal third-quarter revenue of $16.58 billion, topping the analyst consensus of $15.87 billion. Adjusted earnings per share came in at $0.87, beating estimates of $0.73. Operational revenue grew 7% excluding Covid-19 products, while sales from launched and acquired non-Covid assets surged 32%. Pfizer raised its full-year revenue guidance to $62.0 billion to $64.0 billion and adjusted EPS outlook to $2.95 to $3.05, up from prior ranges of $60.5 billion to $62.5 billion and $2.80 to $3.00, respectively.

Citi raised its price target on Pfizer to $30 from $27, while RBC increased its target to $28 from $25. Management said on the earnings call that cost savings will be reinvested into R&D with a focus on oncology and obesity pipelines, targeting approval for a monthly weight-loss injection by 2028. Nearly all of the expected $7.2 billion in net savings are on track to be realized by end-2026.

Based on public media reports. AI-generated; not investment advice.

Source: Market Movers The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.